Gsk Share Discussion Threads

[dr biotech] 10/5/2017 09:17

Actually quite a few weren't so happy at having to move with some admin staff being made redundant. Thats only to be expected though. There and Stevenage are better places than say Pfizers in sandwhich which is a bit of concrete jungle.

[montyhedge] 10/5/2017 08:39

Look after the staff and the staff will look after the company.Always believed in that.

[ny boy] 10/5/2017 08:35

Can't beat a free coffee :-)

[dr biotech] 10/5/2017 08:22

I've been working at GSK recently - they are closing their Harlow site and moving their labs to Ware. Didn't get to talk to anyone with insider information though. For a big pharma its one of the better places to work, free coffee machines amongst other benefits. The campus is pleasant too.

[montyhedge] 10/5/2017 08:18

Target for me is 2075p, GSK shareprice not back to were they were around 20 years ago. One of the best dividend payers, getting that cheque every 13 weeks on the doormat.

[ny boy] 09/5/2017 23:23

1715p first Monty

[montyhedge] 09/5/2017 14:27

1825p here we come boys.

[montyhedge] 09/5/2017 14:26

Ex on Thursday, I love GSK.

[tradermichael] 09/5/2017 07:30

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore.

Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by several big pharma partners including Genentech and GlaxoSmithKline (GSK). Now, the British biotech has added a second lead compound to its discovery collaboration agreement with GSK, securing itself a new milestone payment.

The two partners initiated their collaboration back in 2013 and GSK agreed to pay Immunocore a massive total of £142M (€170M) in potential pre-clinical milestone payments, adding up to £200M (€240M) in milestones — and double digit royalties — for each new therapy that makes it to the market. The pharma giant seems to be intrigued by Immunocore’s ImmTAC technology, which links a T cell receptor (TCR) with an anti-CD3 antibody to flag the cancer cells for T cell-mediated killing.

In contrast to CAR T cells, the TCRs are able to recognize intracellular tumor antigens that are presented on the surface of the tumor cells, allowing for access to a much wider variety of targets. The anti-CD3 effector domain of the ImmTAC is able to bind and efficiently activate the T cell to kill the cancer cells bound by the TCR.

According to Immunocore, the new ImmTAC candidate is relevant in a number of solid cancers including triple negative breast cancers, oesophageal, gastric and ovarian cancers, expanding the indications the company’s technology.

The first ImmTAC program under Immunocore’s GSK collaboration is on track to be submitted as an IND this year and will enter Phase I clinical studies during early 2018, with potential application in Non-Small Cell Lung Cancer (NSCLC), bladder cancer, synovial sarcoma, melanoma and ovarian cancer.

While the immuno-oncology space could not be more crowded right now, both investors and big pharma seem to be confident that Immunocore’s innovative technology bears high potential to tackle the challenging solid tumors.

[ny boy] 08/5/2017 11:35

Looks like investors moving back into blue chips after the Macron victory..markets looking toppy, switch into defensive plays with solid earnings.

[essentialinvestor] 08/5/2017 08:37

Nice open.

[ny boy] 08/5/2017 08:35

Next stop 1715p

[ny boy] 05/5/2017 10:56

All good here, nice divi too

[philanderer] 05/5/2017 09:21

5th may HSBC buy tp 1970p
5th may Liberum buy tp 1900p

reiterations

[essentialinvestor] 03/5/2017 11:19

GBP/USD plays a big part in the share price

If Brexit talks get messy GSK may viewed as a safer haven
than many other UKX stocks.

However it really cannot buck large falls in the UKX, if that were to occur.

[bracke] 03/5/2017 11:14

It closed on the 28 April at 1550. The lowest since then was on 02 May at 1558.

[toffeeman] 03/5/2017 10:03

You are using the wrong chart package MJ - if there is a gap it's 5p

[mj19] 02/5/2017 22:07

Massive gap on open 1550 needs revisiting

[ny boy] 02/5/2017 17:18

All good from here, on the beachfront in Maroc, 25c moving back to test 1615p, then 1715p this quarter

[essentialinvestor] 02/5/2017 16:15

Another expansion of GSK's US manufacturing site at Rockville announced,
the latest expansion to meet growing demand for Benlysta.

[essentialinvestor] 02/5/2017 10:07

If it's of any interest GSK recently presented at the Cowan and Company
healthcare conference outlining their early stage oncology pipeline.

A webcast is available on the GSK investors site, the sound is of poor
quality during the Q&A, however it's audible on the main presentation.

GSK look to be largely targeting third generation immunotherapy.

[alphorn] 02/5/2017 10:06

I think from memory too that it was Belgium and an SKB facility prior to the merger. (The previous Sanofi CEO, Chris Viehbacher, was head of Vaccines).

[essentialinvestor] 02/5/2017 09:57

Alp, yes, from memory their other major vaccine facility is Belgium?,
they have recently committed extra CAPEX to expand their US vaccine manufacturing base.
Trump should approve ).